» Articles » PMID: 39001488

Soluble CD26: From Suggested Biomarker for Cancer Diagnosis to Plausible Marker for Dynamic Monitoring of Immunotherapy

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2024 Jul 13
PMID 39001488
Authors
Affiliations
Soon will be listed here.
Abstract

Soluble CD26 (sCD26), a glycoprotein with dipeptidyl peptidase (DPP4) enzymatic activity, can contribute to early diagnosis of colorectal cancer and advanced adenomas and has been studied, including for prognostic purposes, across various other types of cancer and disease. The latest research in this field has confirmed that most, though not all, serum/plasma sCD26 is related to inflammation. The shedding and/or secretion of sCD26 from different immune cells are being investigated, and blood DPP4 activity levels do not correlate very strongly with protein titers. Some of the main substrates of this enzyme are key chemokines involved in immune cell migration, and both soluble and cell-surface CD26 can bind adenosine deaminase (ADA), an enzyme involved in the metabolism of immunosuppressor extracellular adenosine. Of note, there are T cells enriched in CD26 expression and, in mice tumor models, tumor infiltrating lymphocytes exhibited heightened percentages of CD26+ correlating with tumor regression. We employed sCD26 as a biomarker in the follow-up after curative resection of colorectal cancer for the early detection of tumor recurrence. Changes after treatment with different biological disease-modifying antirheumatic drugs, including Ig-CTLA4, were also observed in rheumatoid arthritis. Serum soluble CD26/DPP4 titer variation has recently been proposed as a potential prognostic biomarker after a phase I trial in cancer immunotherapy with a humanized anti-CD26 antibody. We propose that dynamic monitoring of sCD26/DPP4 changes, in addition to well-known inflammatory biomarkers such as CRP already in use as informative for immune checkpoint immunotherapy, may indicate resistance or response during the successive steps of the treatment. As tumor cells expressing CD26 can also produce sCD26, the possibility of sorting immune- from non-immune-system-originated sCD26 is discussed.

Citing Articles

Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology.

Gaggini M, Sabatino L, Suman A, Chatzianagnostou K, Vassalle C Cells. 2025; 14(5).

PMID: 40072115 PMC: 11898734. DOI: 10.3390/cells14050387.

References
1.
Narducci M, Scala E, Bresin A, Caprini E, Picchio M, Remotti D . Skin homing of Sézary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood. 2005; 107(3):1108-15. DOI: 10.1182/blood-2005-04-1492. View

2.
Matic I, ordic M, Grozdanic N, Damjanovic A, Kolundzija B, Eric-Nikolic A . Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo. BMC Immunol. 2012; 13:48. PMC: 3464610. DOI: 10.1186/1471-2172-13-48. View

3.
Davoodi J, Kelly J, Gendron N, MacKenzie A . The Simpson-Golabi-Behmel syndrome causative glypican-3, binds to and inhibits the dipeptidyl peptidase activity of CD26. Proteomics. 2007; 7(13):2300-10. DOI: 10.1002/pmic.200600654. View

4.
Kojima J, Ueno Y, Kasugai H, Okuda S, Akedo H . Glycylproline dipeptidyl aminopeptidase and gamma-glutamyl transpeptidase in human hepatic cancer and embryonal tissues. Clin Chim Acta. 1987; 167(3):285-91. DOI: 10.1016/0009-8981(87)90348-2. View

5.
Salgado F, Vela E, Martin M, Franco R, Nogueira M, Cordero O . Mechanisms of CD26/dipeptidyl peptidase IV cytokine-dependent regulation on human activated lymphocytes. Cytokine. 2000; 12(7):1136-41. DOI: 10.1006/cyto.1999.0643. View